BridgeBio Pharma (BBIO) stock in focus as its 2024 spinout BridgeBio Oncology merges with Helix to form go public on Nasdaq ...

BofA raised the firm’s price target on BridgeBio (BBIO) to $46 from $45 and keeps a Buy rating on the shares after accounting for the updated ...

Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Free Report) have earned an average recommendation of “Moderate Buy” from the thirteen brokerages that are covering the firm, MarketBeat.com reports ...

We recently published a list of 10 Best Performing Mid Cap Stocks to Buy According to Analysts. In this article, we are going ...

Refinancing term debt facility lowers interest expense, eliminates near-term amortization payments, and significantly extends ...

BridgeBio Pharma stock is trading -36.77% below its average target price of $52.27 after dropping -8.8% during today's ...

Investing.com -- Shares of BridgeBio Pharma, Inc. (NASDAQ: BBIO) dipped 3% in after-hours trading on Monday following the company's announcement of a proposed offering of convertible senior notes to ...

But the direct-to-consumer ad didn't come from Palo Alto-based Bridge Bio (Nasdaq: BBIO); instead it was produced by Pfizer ...

BridgeBio Pharma (NASDAQ:BBIO – Free Report) had its price target lifted by Citigroup from $45.00 to $49.00 in a research ...

We recently published a list of the 10 Best Performing Pharma Stocks So Far in 2025. In this article, we are going to take a ...

If they have decided to invest in BBIO, it probably means they believe it is a solid investment choice. But it could also mean they are buying up shares in an effort to acquire the company or to get ...

In a report released today, Greg Harrison from Scotiabank maintained a Buy rating on BridgeBio Pharma (BBIO – Research Report), with a price ...